Elly Gerald Stoica

Array ( [id] => 19354322 [patent_doc_number] => 12054753 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-06 [patent_title] => Methods of treatment of muscular dystrophy with ALK4:ActRIIB heteromultimers [patent_app_type] => utility [patent_app_number] => 17/134703 [patent_app_country] => US [patent_app_date] => 2020-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 18 [patent_no_of_words] => 63109 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 163 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17134703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19441200 [patent_doc_number] => 12091440 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => IL2 and peptide-MHC complex fusion proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/127380 [patent_app_country] => US [patent_app_date] => 2020-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 132 [patent_no_of_words] => 51289 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17127380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18208061 [patent_doc_number] => 20230054318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => PERSONALIZED TUMOR VACCINE AND USE THEREOF FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/783866 [patent_app_country] => US [patent_app_date] => 2020-12-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30026 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17783866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18964199 [patent_doc_number] => 11897950 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Osteopontin monoclonal antibodies [patent_app_type] => utility [patent_app_number] => 17/112098 [patent_app_country] => US [patent_app_date] => 2020-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 105 [patent_no_of_words] => 24198 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17112098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720149 [patent_doc_number] => 20210087296 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => INHIBITORY ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/110800 [patent_app_country] => US [patent_app_date] => 2020-12-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36596 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 946 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17110800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552171 [patent_doc_number] => 20230250180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => THERAPEUTIC DRUG FOR CARCINOMATOUS PERITONITIS [patent_app_type] => utility [patent_app_number] => 17/780758 [patent_app_country] => US [patent_app_date] => 2020-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8552 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18341909 [patent_doc_number] => 11639383 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Pharmaceutical composition for treatment of cancer, comprising an immune checkpoint inhibitor antibody and a fusion protein comprising an IL-2 mutant and a CD80 extracellular domain [patent_app_type] => utility [patent_app_number] => 17/780364 [patent_app_country] => US [patent_app_date] => 2020-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 76 [patent_no_of_words] => 19983 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18552171 [patent_doc_number] => 20230250180 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => THERAPEUTIC DRUG FOR CARCINOMATOUS PERITONITIS [patent_app_type] => utility [patent_app_number] => 17/780758 [patent_app_country] => US [patent_app_date] => 2020-11-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8552 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18075928 [patent_doc_number] => 20220401540 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 17/780396 [patent_app_country] => US [patent_app_date] => 2020-11-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11590 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17780396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16954923 [patent_doc_number] => 11058751 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-07-13 [patent_title] => Compositions for optimized RAS peptide vaccines [patent_app_type] => utility [patent_app_number] => 17/100630 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 19265 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17100630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16749961 [patent_doc_number] => 20210101970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/100245 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69787 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17100245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17868480 [patent_doc_number] => 20220291216 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PHARMACEUTICALS AND METHODS FOR TREATING HYPOXIA AND SCREENING METHODS THEREFOR [patent_app_type] => utility [patent_app_number] => 17/100272 [patent_app_country] => US [patent_app_date] => 2020-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27188 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17100272 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18793960 [patent_doc_number] => 11827712 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-11-28 [patent_title] => IL13Ra2 binding agents and use thereof [patent_app_type] => utility [patent_app_number] => 16/949900 [patent_app_country] => US [patent_app_date] => 2020-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 43518 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16949900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16710477 [patent_doc_number] => 20210077624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => VEGF Antagonist Formulations [patent_app_type] => utility [patent_app_number] => 16/950584 [patent_app_country] => US [patent_app_date] => 2020-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5207 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950584 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807935 [patent_doc_number] => 20210130488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => METHODS OF TREATING IMMUNOTHERAPY-RELATED TOXICITY USING A GM-CSF ANTAGONIST [patent_app_type] => utility [patent_app_number] => 17/097303 [patent_app_country] => US [patent_app_date] => 2020-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31527 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17097303 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170391 [patent_doc_number] => 20210324061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => GARP-TGF-BETA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/096931 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26868 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20287186 [patent_doc_number] => 20250312429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-09 [patent_title] => ANTI-GUCY2C VACCINES AND VACCINATION [patent_app_type] => utility [patent_app_number] => 17/775561 [patent_app_country] => US [patent_app_date] => 2020-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17775561 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18059369 [patent_doc_number] => 20220390455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-08 [patent_title] => M-PROTEIN ASSAYS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/774818 [patent_app_country] => US [patent_app_date] => 2020-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17774818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17096919 [patent_doc_number] => 20210284710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => SIGLEC-9 ECD FUSION MOLECULES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/088149 [patent_app_country] => US [patent_app_date] => 2020-11-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17088149 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16628768 [patent_doc_number] => 20210047421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => Pharmaceutical Composition for Cancer Treatment [patent_app_type] => utility [patent_app_number] => 17/085040 [patent_app_country] => US [patent_app_date] => 2020-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17274 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17085040 [rel_patent_id] =>[rel_patent_doc_number] =>)